LABCHIP ASSAY DEVELOPMENT Clause Samples
LABCHIP ASSAY DEVELOPMENT. Throughout the Term, LabChip Assays for Amphora's targets will be developed collaboratively by the parties or solely by Amphora, as determined by Amphora. In general, where Caliper is developing a LabChip Assay for Amphora, Amphora will develop the appropriate biochemical and/or cellular reagents for the LabChip Assay and will provide the necessary (as determined by Amphora) quantities of reagents to Caliper. With respect to each Chip for use in a LabChip Assay desired by Amphora, Caliper shall supply such Chip to Amphora in accordance with the terms and conditions in this Agreement, including the ordering and forecasting terms set forth in Section 2.4. Caliper shall use commercially reasonable efforts to make such Chip available to Amphora as soon as possible after Amphora's request.
LABCHIP ASSAY DEVELOPMENT. LabChip Assays for Lilly's Targets will be developed collaboratively by the parties or solely by Lilly, as determined by Lilly. In general, Lilly will [ * ]. Initially, Caliper will be primarily responsible for [ * ]. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
LABCHIP ASSAY DEVELOPMENT. LabChip Assays for Lilly's Targets will be developed collaboratively by the parties or solely by Lilly, as determined by Lilly. In general, Lilly will develop the appropriate biochemical and/or cellular reagents for a Screening assay and will provide necessary quantities of reagents to Caliper as determined by Lilly. Initially, Caliper will be primarily responsible for adapting the Screening assay to the LabChip format. Over time, the parties expect that Lilly will assume an increasing role in developing LabChip Assays and eventually conduct such activities independently. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.